| 前收盘价格 | 0.644 |
| 收盘价格 | 0.669 |
| 成交量 | 27,925 |
| 平均成交量 (3个月) | 55,939 |
| 市值 | 15,117,058 |
| 价格/销量 (P/S) | 1.36 |
| 股市价格/股市净资产 (P/B) | 2.55 |
| 52周波幅 | |
| 利润日期 | 7 Aug 2023 - 11 Aug 2023 |
| 营业毛利率 | -15.45% |
| 营业利益率 (TTM) | -17.43% |
| 稀释每股收益 (EPS TTM) | -2.06 |
| 季度收入增长率 (YOY) | 43.60% |
| 总债务/股东权益 (D/E MRQ) | 19.09% |
| 流动比率 (MRQ) | 0.760 |
| 营业现金流 (OCF TTM) | 1.06 M |
| 杠杆自由现金流 (LFCF TTM) | 1.76 M |
| 资产报酬率 (ROA TTM) | -10.90% |
| 股东权益报酬率 (ROE TTM) | -25.29% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看涨 | 混合的 |
| Diagnostics & Research (全球的) | 看涨 | 混合的 | |
| 股票 | Precipio, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Core |
| 内部持股比例 | 14.13% |
| 机构持股比例 | 7.46% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 14 Nov 2025 | 公告 | Precipio Announces its Q3-2025 Financial Results |
| 04 Nov 2025 | 公告 | Precipio Announces Q3-2025 Shareholder Update Call |
| 02 Sep 2025 | 公告 | Precipio Terminates Its ATM |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合